Cantor Fitzgerald Decreases Earnings Estimates for Metsera

Metsera, Inc. (NASDAQ:MTSR) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings of ($3.58) per share for the year, down from their prior estimate of ($3.38). Cantor Fitzgerald has a “Overweight” rating on the stock.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

A number of other equities analysts have also weighed in on MTSR. Bank of America initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective on the stock. Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating on the stock. Finally, Guggenheim assumed coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price for the company.

Metsera Stock Down 2.8 %

NASDAQ MTSR opened at $27.22 on Monday. Metsera has a 52-week low of $23.08 and a 52-week high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.